Concepedia

Richard N. Sullivan

RN

Statistics

Publications

3

Citations

191

H-Index

3

Active since

2013

Affiliations

Sungkyunkwan University(Current)

Auckland City Hospital

Indiana University Health

Indiana University – Purdue University Indianapolis

Boehringer Ingelheim (Canada)

Richard N. Sullivan is an author at Sungkyunkwan University specializing in cancer pharmacology, oncology, and oncology pharmacotherapy.

Publications per year

2013–2017

3

Publications

3

Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial

Nasser H. Hanna, R. Kaiser, Richard N. Sullivan et al. · Lung Cancer · 2016 · 87 citations

, , +11

Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.

Nasser H. Hanna, R. Kaiser, Richard N. Sullivan et al. · Journal of Clinical Oncology · 2013 · 83 citations

, , +16

Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.

David R. Gandara, Joachim von Pawel, Richard N. Sullivan et al. · Journal of Clinical Oncology · 2017 · 21 citations

, , +16

1–3 of 3